Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
18
08
2020
pubmed:
28
8
2020
medline:
4
6
2021
entrez:
27
8
2020
Statut:
ppublish
Résumé
The Clinicopathological and Gene Expression Profile (CP-GEP) model was developed to accurately identify patients with T1-T3 primary cutaneous melanoma at low risk for nodal metastasis. To validate the CP-GEP model in an independent Dutch cohort of patients with melanoma. Patients (aged ≥ 18 years) with primary cutaneous melanoma who underwent sentinel lymph node biopsy (SLNB) between 2007 and 2017 at the Erasmus Medical Centre Cancer Institute were eligible. The CP-GEP model combines clinicopathological features (age and Breslow thickness) with the expression of eight target genes involved in melanoma metastasis (ITGB3, PLAT, SERPINE2, GDF15, TGFBR1, LOXL4, CXCL8 and MLANA). Using the pathology result of SLNB as the gold standard, performance measures of the CP-GEP model were calculated, resulting in CP-GEP high risk or low risk for nodal metastasis. In total, 210 patients were included in the study. Most patients presented with T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma. Of all patients, 27% (n = 56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54% and 16% of patients with T1, T2, T3 and T4 melanoma, respectively. Overall, the CP-GEP model had a negative predictive value (NPV) of 90·5% [95% confidence interval (CI) 77·9-96.2], with an NPV of 100% (95% CI 72·2-100) in T1, 89·3% (95% CI 72·8-96·3) in T2 and 75·0% (95% CI 30·1-95·4) in T3 melanomas. The CP-GEP indicated high risk in all T4 melanomas. The CP-GEP model is a noninvasive and validated tool that accurately identified patients with primary cutaneous melanoma at low risk for nodal metastasis. In this validation cohort, the CP-GEP model has shown the potential to reduce SLNB procedures in patients with melanoma.
Sections du résumé
BACKGROUND
The Clinicopathological and Gene Expression Profile (CP-GEP) model was developed to accurately identify patients with T1-T3 primary cutaneous melanoma at low risk for nodal metastasis.
OBJECTIVES
To validate the CP-GEP model in an independent Dutch cohort of patients with melanoma.
METHODS
Patients (aged ≥ 18 years) with primary cutaneous melanoma who underwent sentinel lymph node biopsy (SLNB) between 2007 and 2017 at the Erasmus Medical Centre Cancer Institute were eligible. The CP-GEP model combines clinicopathological features (age and Breslow thickness) with the expression of eight target genes involved in melanoma metastasis (ITGB3, PLAT, SERPINE2, GDF15, TGFBR1, LOXL4, CXCL8 and MLANA). Using the pathology result of SLNB as the gold standard, performance measures of the CP-GEP model were calculated, resulting in CP-GEP high risk or low risk for nodal metastasis.
RESULTS
In total, 210 patients were included in the study. Most patients presented with T2 (n = 94, 45%) or T3 (n = 70, 33%) melanoma. Of all patients, 27% (n = 56) had a positive SLNB, with nodal metastasis in 0%, 30%, 54% and 16% of patients with T1, T2, T3 and T4 melanoma, respectively. Overall, the CP-GEP model had a negative predictive value (NPV) of 90·5% [95% confidence interval (CI) 77·9-96.2], with an NPV of 100% (95% CI 72·2-100) in T1, 89·3% (95% CI 72·8-96·3) in T2 and 75·0% (95% CI 30·1-95·4) in T3 melanomas. The CP-GEP indicated high risk in all T4 melanomas.
CONCLUSIONS
The CP-GEP model is a noninvasive and validated tool that accurately identified patients with primary cutaneous melanoma at low risk for nodal metastasis. In this validation cohort, the CP-GEP model has shown the potential to reduce SLNB procedures in patients with melanoma.
Identifiants
pubmed: 32844403
doi: 10.1111/bjd.19499
pmc: PMC8247350
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
944-951Subventions
Organisme : Netherlands National Enterprising Agency (RVO)
Informations de copyright
© 2020 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
Future Oncol. 2019 Apr;15(11):1207-1217
pubmed: 30691297
Cancer. 1989 Jan 1;63(1):181-7
pubmed: 2910416
Int J Cancer. 2018 Apr 15;142(8):1528-1535
pubmed: 29105744
Eur J Cancer. 2018 Nov;103:356-387
pubmed: 30100160
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
JAMA Dermatol. 2020 Jan 1;156(1):57-64
pubmed: 31721989
Eur J Cancer. 2010 Sep;46(13):2414-21
pubmed: 20621467
Am Surg. 2018 May 1;84(5):672-679
pubmed: 29966567
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1713-42
pubmed: 19714329
N Engl J Med. 2014 Feb 13;370(7):663-4
pubmed: 24521113
J Clin Oncol. 2005 Sep 1;23(25):6054-62
pubmed: 16135473
J Clin Oncol. 2013 Dec 10;31(35):4387-93
pubmed: 24190111
N Engl J Med. 2006 Sep 28;355(13):1307-17
pubmed: 17005948
J Clin Oncol. 2009 Apr 10;27(11):1857-63
pubmed: 19273706
Eur J Surg Oncol. 2017 Feb;43(2):270-277
pubmed: 27423448
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
J Eur Acad Dermatol Venereol. 2017 May;31(5):e247-e249
pubmed: 27785829
Ann Surg. 2016 Feb;263(2):392-8
pubmed: 26488806
Eur J Cancer. 2016 Nov;67:164-173
pubmed: 27669503
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Eur J Cancer. 2012 Oct;48(15):2375-90
pubmed: 22981501
J Transl Med. 2019 Aug 14;17(1):266
pubmed: 31412885
Br J Cancer. 2008 Jun 17;98(12):1922-8
pubmed: 18506141
N Engl J Med. 2017 Jun 8;376(23):2211-2222
pubmed: 28591523
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402
pubmed: 30959471
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
J Clin Oncol. 2001 Aug 15;19(16):3622-34
pubmed: 11504744
Arch Surg. 1992 Apr;127(4):392-9
pubmed: 1558490
Int J Cancer. 2017 Apr 15;140(8):1802-1808
pubmed: 28109000
Melanoma Res. 2012 Oct;22(5):386-91
pubmed: 22955010
CA Cancer J Clin. 2017 Nov;67(6):472-492
pubmed: 29028110
Eur J Cancer. 2006 Feb;42(3):372-80
pubmed: 16403622
N Engl J Med. 2014 Feb 13;370(7):599-609
pubmed: 24521106
JCO Precis Oncol. 2020;4:319-334
pubmed: 32405608
Ann Surg Oncol. 2019 May;26(5):1494-1502
pubmed: 30719636
Am J Clin Oncol. 2018 Aug;41(8):754-759
pubmed: 28121641
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835